Sign in →

Test ID: LIPOG Lipodystrophy Gene Panel, Varies


Ordering Guidance


Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Necessary Information


Prior Authorization is available, but not required, for this test. If proceeding with the prior authorization process, submit the required form with the specimen.



Specimen Required


Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated


Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file.

The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Hereditary Dyslipidemia Patient Information

3. Lipodystrophy Gene Panel (LIPOG) Prior Authorization Ordering Instructions

4. If not ordering electronically, complete, print, and send a Cardiovascular Test Request (T724) with the specimen.

Useful For

Providing a genetic evaluation for patients with a personal or family history suggestive of a hereditary lipodystrophy

 

Establishing a diagnosis of a hereditary lipodystrophy

Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

Reporting Name

Lipodystrophy Gene Panel

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Clinical Information

Lipodystrophies are rare conditions characterized primarily by the inability to properly store adipose tissue in the absence of nutritional deficit or catabolic state.(1) Lipodystrophies can be genetic (hereditary) or acquired (caused by environmental factors such as illness). The two most common forms of hereditary lipodystrophies are congenital generalized lipodystrophy (CGL) and familial partial lipodystrophy (FPLD), which are named according to the regions of the body they affect.(1)

 

CGL (also known as Berardinelli-Seip congenital lipodystrophy) is an autosomal recessive condition characterized by generalized absence fat throughout the entire body, generalized muscular appearance, and metabolic complications such as diabetes mellitus and dyslipidemia.(1,2) The prevalence of autosomal recessive CGL is not well-established, with estimates ranging from 1:10,000,000 to 1:25,000 depending on the population being considered.(2) Severe CGL is also a feature of Keppen-Lubinsky syndrome (KPLBS), an extremely rare autosomal dominant condition caused by biallelic, disease-causing variants in the KCNJ6 gene. KPLBS is a syndromic condition characterized by severe generalized lipodystrophy, microcephaly, progeroid appearance, and intellectual disability.(3)

 

FPLD can be inherited in an autosomal dominant or autosomal recessive manner and is characterized by localized absence of fat in the limbs with possible metabolic complications.(1,4) FPLD can be isolated or can be a feature of a syndromic condition such as autosomal dominant SHORT syndrome (short stature, hyperextensibility of joints, ocular depression, Rieger anomaly, and teething delay) and autosomal recessive Mandibuloacral dysplasia with type B lipodystrophy.(4) The prevalence of FPLD is not known but thought to be rare.(4)

 

Disease-causing variants in the LMNA gene can lead to autosomal recessive and autosomal dominant forms of lipodystrophies, but variants in this gene are also associated with several autosomal dominant cardiac, connective tissue, and muscular dystrophy phenotypes.(4) Often, lipodystrophy is a single feature of a more syndromic condition when caused by disease-causing LMNA variants.(4)

 

The FBN1 gene is primarily associated with autosomal dominant Marfan syndrome without features of lipodystrophy. However, literature suggests that specific disease-causing variants in the FBN1 gene may lead to an overlapping phenotype characterized by partial features of Marfan syndrome, progeroid appearance, and clinical features of lipodystrophy.(5)

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(6) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Clinical Reference

1. Brown RJ, Araujo-Vilar D, Cheung PT, et al: The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. doi: 10.1210/jc.2016-2466

2. Van Maldergem L: Berardinelli-Seip congenital lipodystrophy. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2003. Updated December 8, 2016. Accessed July 26, 2022. Available at www.ncbi.nlm.nih.gov/books/NBK1212/

3. Masotti A, Uva P, Davis-Keppen L, et al: Keppen-Lubinsky syndrome is caused by mutations in the inwardly rectifying K+ channel encoded by KCNJ6. Am J Hum Genet. 2015 Feb;96(2):295-300. doi: 10.1016/j.ajhg.2014.12.011

4. Bagias C, Xiarchou A, Bargiota A, Tigas S: Familial partial lipodystrophy (FPLD): recent insights. Diabetes Metab Syndr Obes. 2020 May;13:1531-1544. doi: 10.2147/DMSO.S206053

5. Passarge E, Robinson PN, Graul-Neumann LM: Marfanoid-progeroid-lipodystrophy syndrome: a newly recognized fibrillinopathy. Eur J Hum Genet. 2016 Aug;24(9):1244-1247. doi: 10.1038/ejhg.2016.6

6. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424. doi: 10.1038/gim.2015.30

Day(s) Performed

Varies

Report Available

28 to 42 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81406 x2

81408

81479

LOINC Code Information

Test ID Test Order Name Order LOINC Value
LIPOG Lipodystrophy Gene Panel 51966-0

 

Result ID Test Result Name Result LOINC Value
617338 Test Description 62364-5
617339 Specimen 31208-2
617340 Source 31208-2
617341 Result Summary 50397-9
617342 Result 82939-0
617343 Interpretation 69047-9
617344 Additional Results 82939-0
617345 Resources 99622-3
617346 Additional Information 48767-8
617347 Method 85069-3
617348 Genes Analyzed 48018-6
617349 Disclaimer 62364-5
617350 Released By 18771-6
Mayo Clinic Laboratories | Cardiology Catalog Additional Information:

multi-gene panel